BriaCell Therapeutics Corp (BCTX)
0.5934
-0.01
(-1.03%)
USD |
NASDAQ |
Nov 14, 16:00
0.6002
+0.01
(+1.15%)
After-Hours: 18:04
BriaCell Therapeutics Net Income (Quarterly): -1.214M for July 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2024 | -1.214M |
| April 30, 2024 | 1.716M |
| January 31, 2024 | -11.29M |
| October 31, 2023 | 6.002M |
| July 31, 2023 | -2.419M |
| April 30, 2023 | -4.895M |
| January 31, 2023 | -11.88M |
| October 31, 2022 | -1.106M |
| July 31, 2022 | -0.4504M |
| April 30, 2022 | -10.02M |
| January 31, 2022 | 11.16M |
| October 31, 2021 | -27.53M |
| July 31, 2021 | -16.11M |
| April 30, 2021 | 2.950M |
| January 31, 2021 | -0.2359M |
| October 31, 2020 | -0.4213M |
| July 31, 2020 | -0.9627M |
| April 30, 2020 | -0.5049M |
| January 31, 2020 | -1.425M |
| October 31, 2019 | -1.251M |
| July 31, 2019 | -1.670M |
| April 30, 2019 | -1.132M |
| January 31, 2019 | -1.205M |
| October 31, 2018 | -0.7984M |
| July 31, 2018 | -1.609M |
| Date | Value |
|---|---|
| April 30, 2018 | -1.290M |
| January 31, 2018 | -0.7873M |
| October 31, 2017 | -0.4996M |
| July 31, 2017 | -1.098M |
| April 30, 2017 | -0.861M |
| January 31, 2017 | -0.3163M |
| October 31, 2016 | -0.3274M |
| July 31, 2016 | -0.2394M |
| April 30, 2016 | -0.3407M |
| January 31, 2016 | -0.7136M |
| October 31, 2015 | -0.3082M |
| July 31, 2015 | -0.0895M |
| April 30, 2015 | -0.3858M |
| January 31, 2015 | -2.036M |
| October 31, 2014 | -0.0546M |
| July 31, 2014 | -7.382M |
| April 30, 2014 | -0.5383M |
| January 31, 2014 | -0.0796M |
| October 31, 2013 | -0.1518M |
| July 31, 2013 | -0.0963M |
| April 30, 2013 | -0.1106M |
| January 31, 2013 | -0.0849M |
| October 31, 2012 | -0.0787M |
| July 31, 2012 | -0.4954M |
| April 30, 2012 | -0.3748M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-27.53M
Minimum
Oct 2021
11.16M
Maximum
Jan 2022
-3.613M
Average
-1.106M
Median
Oct 2022
Net Income (Quarterly) Benchmarks
| CeCors Inc | -- |
| Venus Concept Inc | -19.95M |
| Aurinia Pharmaceuticals Inc | 14.35M |
| Edesa Biotech Inc | -1.668M |
| Lexaria Bioscience Corp | -1.782M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.768M |
| EPS Diluted (Quarterly) | -0.07 |
| Enterprise Value | 20.53M |
| Earnings Yield | -197.2% |